Hematology/Oncology

Top Story

Simulation model provides more accurate estimate of cancer progression in Barrett's esophagus

September 3, 2015

Simulation modeling revealed that the lower estimates of the rate of progression from Barrett’s esophagus to esophageal adenocarcinoma from population-based studies are likely more accurate than higher estimates from prospective studies due to detection bias from endoscopic surveillance.

Because the true risk of progression from BE to cancer is uncertain, researchers used the ERASMUS/UW esophageal adenocarcinoma model — which was previously developed by Erasmus Medical Center University in the Netherlands and the University of Washington — to more accurately estimate cancer incidence in BE by reconciling published data.

In the Journals

Imetelstat demonstrates safety, efficacy for essential thrombocythemia

September 3, 2015
Patients with essential thrombocythemia who did not respond to or had unacceptable side effects from previous therapies experienced rapid and durable hematologic and…

Novartis receives EU approval for combination treatment of metastatic melanoma

September 3, 2015
Novartis has received European Commission approval for the combination of Tafinlar and Mekinist to treat metastatic melanoma with a BRAF V600 mutation, according to a…
Ahmedin Jemal, DVM, PhD In the Journals

Contralateral prophylactic mastectomy incidence increases among men with breast cancer

September 3, 2015
The use of contralateral prophylactic mastectomy has increased among men diagnosed with unilateral breast cancer, according to study results published in JAMA
In the Journals

Curettage suggested as first treatment for tumorinduced osteomalacia lesions in long bone

September 3, 2015
As researchers of this retrospective study of 17 patients with tumor-induced osteomalacia lesions in long bones found 82% of tumors were located in the epiphysis, they…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
morganatic-roan